Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.65 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929685 | 0.95 | GABRA5 (0.60) | GABRA5CXCR2GABRA1CHRNB2CHRNA7 | |
| SCHEMBL12398738 | 0.94 | GABRA5 (0.59) | GABRA5CXCR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6928096 | 0.92 | GABRA5 (0.61) | GABRA5CXCR2GABRA1 | |
| SCHEMBL6930855 | 0.87 | GABRA5 (0.66) | GABRA5CXCR2GABRA1 | |
| SCHEMBL1461190 | 0.83 | CHRM4 (0.53) | GABRA5CXCR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6927885 | 0.82 | GABRA5 (0.60) | GABRA5CXCR2 | |
| SCHEMBL6930206 | 0.81 | GABRA5 (0.64) | GABRA5CXCR2 | |
| SCHEMBL6930892 | 0.81 | GABRA5 (0.64) | GABRA5 | |
| SCHEMBL28703922 | 0.80 | CXCR2 (0.64) | CXCR2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6931281 | 0.80 | GABRA5 (0.61) | GABRA5CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GABRA5 26/4885CXCR2 2454/4885GABRA1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.